US 10738116
Dual specific anti-CD22-anti-CD19 chimeric antigen receptors
granted A61PA61P35/00
Quick answer
US patent 10738116 (Dual specific anti-CD22-anti-CD19 chimeric antigen receptors) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America, as represented by the Secretary, Department of Health and Human Services
- Grant date
- Tue Aug 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 24
- CPC classes
- A61P, A61P35/00